Immix Biopharma Investor Presentation Deck
IMX-110 MoA: Tissue-Specific Therapeutic™ with TME Normalization™ Technology
www.
●
●
IMX-110: FIRST TARGETED ONCOLOGY MICELLE TO ACHIEVE "SMALL MOLECULE PENETRATION"
- www
-PEG-PE
-DOX
- CUR
www.
www.
O
14-16nm diameter
wwwww.
IgG Antibody: 10-15nm diameter
www.
BCL-x
BCL
-my
arvivi
IMX-110
PI3K
AKT
Upregulation in Cancer
¡MX-110 Downregulation.
||||||
||
0
O
NFKB
COX2
spase
0
Jak
STAT
Cell Death
O
¡MX-110 DNA Damage
IMX-110 Upregulation
0
¡MX-110
Disperses Throughout Cell
TUPT
Lil
IMX-110 - Key Characteristics
Get There: Deliver Payload Deep Into
the Tumor Microenvironment
Stay There: Accumulate in Tumors
% of dose / g organ
Kill Tumors: 12x Tumor Killing vs SoC
1%
Control
1
0
intensity (a.u.)
(g)
600 -12nm
-60nm
-125nm
200
15%
-200
10
10 20 30
Time (h)
Free DOX
●●●
S
40
80
distance from vessel (um)->
(Adapted from Popovic et al, 2010)
40
IMMIX
BIOPHARMA
IMX-110 is a negatively-charged Tissue-Specific Therapeutic™ built on our TME
Normalization™ Technology encapsulating a synergistic 5:1 ratio of
poly-kinase inhibitor (polyphenol curcuminoid complex, or PCC) and apoptosis
inducer (PEG-PE doxorubicin complex) delivered deep into the TME.
First Oncology Micelle to achieve "small molecule penetration"
Electrostatic charge attracts to tumor like a magnet
Resulting in 1,200% increase in apoptosis (tumor cell death) vs. conventional
therapies
33
Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol. 2022.281628. Epub ahead of print. PMID: 36200421. Stan, S. D. et al. Nat. Rev. Gastroenterol. Hepatol. 7, 347-356
(2010); published online 4 May 2010. http://www.nature.com/doifinder/10.1038/nrgastro.2010.61. Popovic et al, A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010 Nov 8; 49(46): 8649-8652. https://dx.doi.org/10.1002%2Fanie.201003142; M Yokoyama, T Okano, Y Sakurai, S Fukushima, K Okamoto, K
Kataoka. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. https://doi.org/10.3109/10611869909085500; Sarisozen et. al. (2016- https://doi.org/10.1016/j.ejpb.2016.08.013).
Caspase 3/7 Increase (%) vs. Control (empty micelle) as an indicator of tumor apoptosis, after 24h
1,200% increase
181%
penetration depth
35%
Micellular DOX
Free DOX
53%
DOX micelles. CUR micelles
iMX-110View entire presentation